CorFlow Therapeutics has successfully completed the second close of its Seed+ financing round. To date, the company has raised a total of 9.4 million Swiss francs in seed funding from private investors, according to a press release.
Located in Baar in the canton of Zug, CorFlow has developed a technology for detecting and treating Microvascular Obstruction (MVO) following a heart attack. MVO is a typical side effect of an acute infarction and is associated with a worsened outcome. With the new funds, the company can now proceed with the first clinical trials. Its system will be studied in 40 acute heart attack patients in Switzerland, Germany, Belgium and the UK.
The milestones to be reached over the coming months through the clinical trials will form the basis for launching an A financing round in 2019 to secure the long-term R&D, clinical and regulatory activities.
More News
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space